My company is evaluating the opportunity to import drug product to Canada, what considerations and/or differences would you highlight as different from the US market from a regulatory perspective?
____________________________________________
Gwendolyn Lohr
QA Regulatory & Compliance Specialist
Novo Nordisk Pharmaceutical Industries, LP
3612 Powhatan Road
Clayton NC 27527
USA
919 274 7383 (mobile)
gwwa@novonordisk.com
Changing the future of urban diabetes
Did you know that 2/3 of people with diabetes live in cities? Find out more here
This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.